NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2020; 15 (4): 429 - 483 C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 480 Consenso chileno para la atención integral de niños y adultos con fibrosis quística 2):ii1–64. 65. Waters V, Ratjen F. Antibiotic treatment for nontubercu- lous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;2016(12). 66. Brandt C, Roehmel J, Rickerts V, Melichar V, Niemann N, Schwarz C. Aspergillus Bronchitis in Patients with Cystic Fibrosis. Mycopathologia. 2018;183(1):61–9. 67. Izumikawa K, Yamamoto Y, Mihara T, Takazono T, Morina- ga Y, Kurihara S, et al. Bronchoalveolar lavage galacto- mannan for the diagnosis of chronic pulmonary aspergi- llosis. Med Mycol. 2012;87(8):811–7. 68. Tracy MC, Okorie CUA, Foley EA, Moss RB. Allergic bron- chopulmonary aspergillosis. J Fungi. 2016;2(2). 69. King J, Brunel SF, Warris A. Aspergillus infections in cys- tic fibrosis. J Infect. 2016;72:S50–5. 70. Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richard- son MD, et al. Novel immunologic classification of asper- gillosis in adult cystic fibrosis. J Allergy Clin Immunol. 2013;132(3). 71. Burgel PR, Paugam A, Hubert D, Martin C. Aspergillus fumigatus in the cystic fibrosis lung: Pros and cons of azole therapy. Infect Drug Resist. 2016;9:229–38. 72. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic Bronchopulmonary Aspergi- llosis in Cystic Fibrosis - State of the Art: Cystic Fibro- sis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl. 3). 73. Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Diagno- sing Allergic Bronchopulmonary Aspergillosis: A Review. Cureus. 2019;11(4). 74. Ghdifan S, Couderc L, Michelet I, Leguillon C, Masseli- ne B, Marguet C. Bolus methylprednisolone efficacy for uncontrolled exacerbation of cystic fibrosis in children. Pediatrics. 2010;125(5). 75. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros. 2009;8(4):253–7. 76. Elphick HE, Southern KW. Antifungal therapies for aller- gic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;2016(11). 77. Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84. 78. Godet C, Goudet V, Laurent F, Moal G Le, Gounant V, Frat JP, et al. Nebulised liposomal amphotericin B for Asper- gillus lung diseases: Case series and literature review. Mycoses. 2015;58(3):173–80. 79. Parisi GF, Portale A, Papale M, Tardino L, Rotolo N, Licari A, et al. Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fi- brosis: Case reports and literature review. J Allergy Clin Immunol Pract. 2019;7(5):1636–8. 80. Deschamp AR, Hatch JE, Slaven JE, Gebregziabher N, Storch G, Hall GL, et al. Early respiratory viral in- fections in infants with cystic fibrosis. J Cyst Fibros. 2019;18(6):844–50. 81. Waters V, Ratjen F. Pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2015;12:S200–6. 82. Wark P, Mcdonald VM. Nebulised hypertonic saline for cys- tic fibrosis. Cochrane Database Syst Rev. 2018;2018(9). 83. Tarran R, Donaldson S, Boucher RC. Rationale for hyper- tonic saline therapy for cystic fibrosis lung disease. Se- min Respir Crit Care Med. 2007;28(3):295–302. 84. Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, et al. Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fi- brosis. Pediatrics. 2016;137(4). 85. Dellon EP, Donaldson SH, Johnson R, Davis SD. Sa- fety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43(11):1100–6. 86. Rosenfeld M, Davis S, Brumback L, Daniel S, Row- botham R, Johnson R, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Short-term tolerability, adherence, and safety. Pediatr Pulmonol. 2011;46(7):666–71. 87. Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;2018(9). 88. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et al. Clinical use of dornase alfa is associa- ted with a slower rate of FEV 1 decline in cystic fibrosis. Pediatr Pulmonol. 2011;46(6):545–53. 89. Dentice R, Elkins M. Timing of dornase alfa inhala- tion for cystic fibrosis. Cochrane Database Syst Rev. 2016;2016(7). 90. Cheng K, Ashby D, Smyth RL. Oral steroids for long- term use in cystic fibrosis. Cochrane Database Syst Rev. 2015;2015(12). 91. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cys- tic fibrosis. Cochrane Database Syst Rev. 2016;2016(8). 92. Principi N, Blasi F, Esposito S. Azithromycin use in pa- tients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2015;34(6):1071–9. 93. Wilms EB, Touw DJ, Heijerman HGM, Van Der Ent CK. Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharma- cokinetics, efficacy, and side effects. Pediatr Pulmonol. 2012;47(7):658–65. 94. Lands LC, Stanojevic S. Oral non-steroidal anti-inflam- matory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019;2019(9). 95. Laube BL, Janssens HM, De Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–31. 96. Saiman L, Siegel J. Infection Control in Cystic Fibrosis. Vol. 17, Clinical Microbiology Reviews. American Society for Microbiology (ASM); 2004. p. 57–71. 97. Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update. Infect Control Hosp Epidemiol. 2014;35(S1):s1–67. 98. King CS, Brown AW, Aryal S, Ahmad K, Donaldson S. Cri- tical Care of the Adult Patient With Cystic Fibrosis. Chest. 2019;155(1):202–14. 99. Kioumis I, Zarogoulidis K, Huang H, Li Q, Dryllis G, Pitsiou G, et al. Pneumothorax in cystic fibrosis. J Thorac Dis.